Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer

被引:5
|
作者
Murakami, Kaoru [1 ]
Furuya, Hideki [1 ]
Hokutan, Kanani [2 ,3 ]
Goodison, Steve [4 ]
Pagano, Ian [5 ]
Chen, Runpu [6 ]
Shen, Cheng-Huang [7 ]
Chan, Michael W. Y. [8 ]
Ng, Chi Fai [9 ]
Kobayashi, Takashi [10 ]
Ogawa, Osamu [10 ]
Miyake, Makito [11 ]
Thornquist, Mark [12 ]
Shimizu, Yoshiko [2 ,3 ]
Hayashi, Kazukuni [2 ]
Wang, Zhangwei [5 ]
Yu, Herbert [5 ]
Rosser, Charles J. [1 ]
机构
[1] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Univ Hawaii, Clin & Translat Res Program, Canc Ctr, Honolulu, HI 96813 USA
[3] Univ Hawaii Manoa, Dept Mol Biosci & Bioengn, Honolulu, HI 96822 USA
[4] Mayo Clin, Dept Quantitat Hlth Sci, Jacksonville, FL 32224 USA
[5] Univ Hawaii Canc Ctr, Populat Sci Pacific Program, Honolulu, HI 96813 USA
[6] SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14260 USA
[7] Yi Christian Hosp, Ditmanson Med Fdn Chia, Dept Urol, Chiayi 600, Taiwan
[8] Natl Chung Cheng Univ, Dept Biomed Sci, Chiayi 621, Taiwan
[9] Chinese Univ Hong Kong, SH Ho Urol Ctr, Dept Surg, Hong Kong, Peoples R China
[10] Kyoto Univ, Dept Urol, Grad Sch Med, Kyoto 6068507, Japan
[11] Nara Med Univ, Dept Urol, Nara 6348522, Japan
[12] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
关键词
plasminogen activator inhibitor-1; bladder cancer; 3 &' UTR SNP; recurrence; survival; apoptosis; Claspin; PLASMINOGEN-ACTIVATOR INHIBITOR-1; CONTACT INHIBITION; EXPRESSION; SURVIVAL; CHEMOTHERAPY; POLYMORPHISM; CLASPIN; SILENT; GROWTH; SITES;
D O I
10.3390/ijms24054943
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Simple SummaryBladder cancer (BCa) is one of the most common cancer types worldwide and is characterized by a high rate of recurrence. Previous studies have demonstrated that plasminogen activator inhibitor-1 (PAI1) plays an important role in bladder cancer development. The aim of our retrospective study was to assess the effects of PAI1 mutational status in bladder tumors. In this study, we evaluated the mutational status of PAI1 in a series of independent cohorts, comprised of a total of 660 subjects. We identified two clinically relevant 3 ' untranslated region (UTR) single nucleotide polymorphisms (SNPs) in PAI1. Caucasian patients with at least one of the SNPs had a high risk of recurrence and shorter survival. Additional studies using cell lines demonstrated that one SNP increased the anti-apoptotic effect of PAI1, and another lost the control of cancer cellular growth. This study underscores the relevance and influence of these SNPs in bladder cancer.Purpose: Bladder cancer (BCa) is one of the most common cancer types worldwide and is characterized by a high rate of recurrence. In previous studies, we and others have described the functional influence of plasminogen activator inhibitor-1 (PAI1) in bladder cancer development. While polymorphisms in PAI1 have been associated with increased risk and worsened prognosis in some cancers, the mutational status of PAI1 in human bladder tumors has not been well defined. Methods: In this study, we evaluated the mutational status of PAI1 in a series of independent cohorts, comprised of a total of 660 subjects. Results: Sequencing analyses identified two clinically relevant 3 ' untranslated region (UTR) single nucleotide polymorphisms (SNPs) in PAI1 (rs7242; rs1050813). Somatic SNP rs7242 was present in human BCa cohorts (overall incidence of 72%; 62% in Caucasians and 72% in Asians). In contrast, the overall incidence of germline SNP rs1050813 was 18% (39% in Caucasians and 6% in Asians). Furthermore, Caucasian patients with at least one of the described SNPs had worse recurrence-free survival and overall survival (p = 0.03 and p = 0.03, respectively). In vitro functional studies demonstrated that SNP rs7242 increased the anti-apoptotic effect of PAI1, and SNP rs1050813 was related to a loss of contact inhibition associated with cellular proliferation when compared to wild type. Conclusion: Further investigation of the prevalence and potential downstream influence of these SNPs in bladder cancer is warranted.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Clinical outcome of chemoradiotherapy for T1G3 bladder cancer
    Inoue, Masaharu
    Ishioka, Jun-ichiro
    Fukuda, Hiroshi
    Kageyama, Yukio
    Saito, Yoshihiro
    Higashi, Yotsuo
    INTERNATIONAL JOURNAL OF UROLOGY, 2008, 15 (08) : 747 - 750
  • [32] The association between NOTCH3 expression and the clinical outcome in the urothelial bladder cancer patients
    Petrovic, Ana Ristic
    Stokanovic, Dragana
    Stojnev, Slavica
    Floranovic, Milena Potic
    Krstic, Miljan
    Djordjevic, Ivana
    Skakic, Aleksandar
    Velickovic, Ljubinka Jankovic
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2022, 22 (04) : 523 - 530
  • [33] Random Forest and Gene Networks for Association of SNPs to Alzheimer's Disease
    Araujo, Gilderlanio S.
    Souza, Manuela R. B.
    Oliveira, Joao Ricardo M.
    Costa, Ivan G.
    ADVANCES IN BIOINFORMATICS AND COMPUTATIONAL BIOLOGY, 2013, 8213 : 104 - 115
  • [34] IL10 SNPs in acute anterior uveitis - association with disease outcome
    Niemczyk, E.
    Martin, T.
    Smith, J.
    Murray, P.
    Wallace, G.
    IMMUNOLOGY, 2010, 131 : 138 - 138
  • [35] Association of cyclooxygenase-2 immunoreactivity with tumor recurrence and disease progression in superficial urothelial bladder cancer
    Mokos, Ivica
    Jakic-Razumovic, Jasminka
    Marekovic, Zvonimir
    Pasini, Josip
    TUMORI JOURNAL, 2006, 92 (02): : 124 - 129
  • [36] Association of immunity-related gene SNPs with Alzheimer's disease
    Bissar, Nisrine
    Kassir, Rayan
    Salami, Ali
    El Shamieh, Said
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2024, 249
  • [37] Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder Cancer
    Dalbagni, Guido
    Vora, Kinjal
    Kaag, Matthew
    Cronin, Angel
    Bochner, Bernard
    Donat, S. Machele
    Herr, Harry W.
    EUROPEAN UROLOGY, 2009, 56 (06) : 903 - 909
  • [38] Prognostic significance of uPA and PAI-1 in relation to other prognosticators for the clinical outcome of breast cancer
    Knoop, AS
    Laenkholm, AV
    Hansen, S
    Andersen, J
    Andreasen, PA
    Anderson, JA
    Overgaard, J
    Rose, C
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 648 - 648
  • [39] Bladder cancer outcome and subtype classification by gene expression
    Blaveri, E
    Simko, JP
    Korkola, JE
    Brewer, JL
    Baehner, F
    Mehta, K
    DeVries, S
    Koppie, T
    Pejavar, S
    Carroll, P
    Waldman, FM
    CLINICAL CANCER RESEARCH, 2005, 11 (11) : 4044 - 4055
  • [40] IL35 predicts prognosis in gastric cancer and is associated with angiogenesis by altering TIMP1, PAI1 and IGFBP1
    Li, Xiao
    Niu, Nan
    Sun, Jing
    Mou, Yiping
    He, Xujun
    Mei, Linhang
    FEBS OPEN BIO, 2020, 10 (12): : 2687 - 2701